Cure8 research brief
Fecal calprotectin is commonly used to monitor IBD activity. If bowel prep raises calprotectin modestly, that could affect how post-procedure results are interpreted and avoid unnecessary treatment changes.
Adults with ulcerative colitis who undergo colonoscopy, gastroenterologists and clinicians who interpret calprotectin, and researchers studying IBD biomarkers or colonoscopy-related effects.
The study focused on fecal calprotectin measurements before and after PEG-based bowel preparation in people with UC in remission. On average calprotectin rose modestly after prep; the increase was more noticeable in those with mild endoscopic activity (Mayo 1). Most patients did not experience clinical deterioration following the prep.
This finding suggests clinicians and patients should interpret a small post-colonoscopy calprotectin rise with caution—particularly if the patient recently had PEG prep and had mild residual endoscopic activity—rather than assuming it represents a true clinical flare.
The study appears to be a prospective paired-sample design reported as an abstract in Inflammatory Bowel Diseases; details such as sample size, exact timing of stool collection, and statistical estimates are not included here.
This classification and brief are grounded in the article abstract (structured content depth: abstract). The abstract provides a high-level result but does not include full methods, sample size, timing of measurements, or detailed statistics; those details would be needed to change confidence or guide specific clinical decisions.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Non-invasive biomarkers that reflect mucosal inflammation and systemic disease activity could help reduce reliance on frequent endoscopy and guide monitoring for people with Crohn’s disease or ulcerative colitis.
A non-invasive test (intestinal ultrasound) that predicts whether patients stay on biologic therapy could reduce the need for frequent endoscopy and help guide monitoring decisions.
A blood biomarker (OSM) that tracks microscopic inflammation could help detect residual disease activity that fecal calprotectin and routine clinical scores miss. That matters because histological inflammation predicts...
